Previous 10 | Next 10 |
Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients KOL Event will be held Thursday, November 11th at 11:30 a.m. ET PR Newswire CRANFORD, N.J. , Oct. 25, 2021 /PRNewswire/ -- ...
3 Hot Penny Stocks You Should Know About Right Now With October more than half way done, investors continue to search for the best penny stocks to buy. Given that this month has already proven itself to be quite bullish, many investors are excited about the future. And recently, stronge...
Are These The Best Penny Stocks To Watch This Week? Here we are at the start of a new week and a new list of penny stocks to watch. This has become a frequent installment on our weekly outlook on markets with a focus on one industry. Biotechnology is one of the areas of the stock market...
Citius Pharmaceuticals to Host Investor Webcast to Discuss the Acquisition of Late Phase 3 Cancer Immunotherapy I/ONTAK (E7777) Investor Webcast will be held on October 20, 2021 at 8:30 a.m. ET PR Newswire CRANFORD, N.J. , Oct. 13, 2021 /PRNewswire/ -- ...
Citius Pharmaceuticals to Present at Upcoming October Investor Conferences Presentations to feature Company's diversified pipeline of critical care products with five active programs PR Newswire CRANFORD, N.J. , Oct. 6, 2021 /PRNewswire/ -- Citius Pharmaceuti...
Temple University Renames College of Liberal Arts Main Campus Building in Honor of Citius Pharmaceuticals Executive Chairman Leonard Mazur Honor recognizes Leonard and Helena Mazur's philanthropic contributions and continued commitment to Temple University student and alumni pro...
Citius stock price reacted to no safety concerns identified by the DMC, to surge 102.86% (YoY) and +108.82% (YTD). Citius has prioritized E7777 threatening to derail the company's progression with Mino-Lok. Continual medical development may overthrow the use of CVCs due to the hig...
Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021 Discussion to feature diversified clinical pipeline with five active programs PR Newswire CRANFORD, N.J. , Sept. 14, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (...
Citius Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15 Citius to highlight addition of Phase 3 cancer immunotherapy to its late-stage pipeline PR Newswire CRANFORD, N.J. , Sept. 8, 2021 /PRNewswire/ -...
Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications Citius expands late-stage pipeline with the acquisition of Dr. Reddy's exclusive license ...
News, Short Squeeze, Breakout and More Instantly...
Citius Pharmaceuticals Inc. Company Name:
CTXR Stock Symbol:
NASDAQ Market:
Citius Pharmaceuticals Inc. Website:
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - July 18, 2024) - Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage biopharmaceutical c...
2024-07-17 10:10:00 ET July 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compan...